| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
PEGs
PROTAC Linkers. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
As a linker molecule, Bis-acrylate-PEG6 itself has no intrinsic biological activity; it serves as a structural connector to join two thiol-containing ligands (e.g., two target protein ligands, two E3 ligase ligands, or one of each) in the synthesis of PROTAC molecules or other bioconjugates. The acrylate groups undergo Michael addition with thiol groups at neutral to slightly basic pH (pH 7.5-8.5) to form stable thioether bonds. This reaction is specific and efficient, making it ideal for conjugations in aqueous buffers. The PEG6 spacer provides flexibility and water solubility, which facilitates the formation of the ternary complex required for targeted protein degradation. The symmetric nature allows for the synthesis of homodimeric PROTACs or the conjugation of two identical ligands. |
| ln Vivo |
No specific in vivo activity has been reported for this linker alone; its activity is derived from the final PROTAC molecule after conjugation with appropriate ligands. The in vivo efficacy of a complete PROTAC is determined in animal models.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. As a synthetic intermediate, its quality is typically confirmed by analytical methods such as HPLC and NMR, with a standard purity of ≥95%. The acrylate groups can be characterized by their characteristic vinyl protons in NMR (multiplets around 5.8-6.5 ppm). The PEG6 spacer can be confirmed by mass spectrometry.
|
| Cell Assay |
N/A; this linker is not tested alone in cell-based assays. It is used as a building block for constructing PROTACs. In a typical conjugation reaction, the acrylate groups are reacted with thiol-containing ligands (e.g., a thiol-functionalized target protein ligand and a thiol-functionalized E3 ligase ligand) in a buffer such as PBS (pH 7.5-8.5) at room temperature for 1-4 hours. The resulting PROTAC is then tested in cells for target degradation activity. The PEG6 spacer improves water solubility, facilitating the reaction in aqueous buffers.
|
| Animal Protocol |
N/A; no animal studies are performed with the linker alone. For a complete PROTAC conjugate, in vivo studies are conducted following institutional guidelines. The compound is typically formulated using a vehicle containing DMSO, PEG300, Tween-80, and saline and administered via intraperitoneal (IP) or intravenous (IV) injection. The PEG6 spacer may improve the pharmacokinetic properties of the conjugate by enhancing water solubility and reducing aggregation.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 390.43, a molecular formula of C18H30O9, and a standard purity of ≥95%. The IUPAC name is 2,2′-((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl) diacrylate (PEG6 diacrylate). For storage, it should be kept at -20degC for up to 3 years, sealed, away from moisture. It is soluble in DMSO and other organic solvents. The product should be stored in a sealed container, protected from light. The acrylate groups are polymerizable and should be handled with care. CAS: 85136-58-9.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human or veterinary use. Standard chemical safety precautions should be observed during handling. The acrylate groups are reactive and should be handled with care to avoid premature polymerization. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license. This compound is not an approved drug and has not been cleared for clinical use.
|
| References |
[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
|
| Additional Infomation |
The homobifunctional nature of Bis-acrylate-PEG6 allows for the synthesis of symmetric PROTAC molecules (where both ends are conjugated to the same type of ligand, e.g., a homodimeric PROTAC) or the conjugation of two different ligands via sequential thiol-Michael addition. The acrylate-thiol Michael addition is a robust, efficient, and mild conjugation chemistry that does not require catalysts and proceeds with high selectivity in aqueous buffers. The PEG6 spacer provides a long, flexible, and hydrophilic linker that is optimal for many PROTAC applications. This linker is also widely used in polymer chemistry for the preparation of hydrogels and crosslinked networks.
|
| Molecular Formula |
C18H30O9
|
|---|---|
| Molecular Weight |
390.43
|
| Exact Mass |
390.189
|
| CAS # |
85136-58-9
|
| PubChem CID |
11058231
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.101g/cm3
|
| Boiling Point |
459.125ºC at 760 mmHg
|
| Flash Point |
196.816ºC
|
| Index of Refraction |
1.46
|
| LogP |
0.527
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
27
|
| Complexity |
362
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C=CC(=O)OCCOCCOCCOCCOCCOCCOC(=O)C=C
|
| InChi Key |
DMMSYVRRDYJQSI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H30O9/c1-3-17(19)26-15-13-24-11-9-22-7-5-21-6-8-23-10-12-25-14-16-27-18(20)4-2/h3-4H,1-2,5-16H2
|
| Chemical Name |
2-[2-[2-[2-[2-(2-prop-2-enoyloxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5613 mL | 12.8064 mL | 25.6128 mL | |
| 5 mM | 0.5123 mL | 2.5613 mL | 5.1226 mL | |
| 10 mM | 0.2561 mL | 1.2806 mL | 2.5613 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
